Global Research Trends on the Treatment of Diffuse Large B-Cell Lymphoma: A Bibliometric and Visualized Study

被引:4
作者
Duan, Qintong [1 ]
Li, Yufeng [1 ]
Ou, Lijia [1 ]
Li, Yajun [2 ]
Zeng, Ruolan [2 ]
He, Yizi [2 ]
Pan, Tao [2 ]
Chen, Siwei [1 ]
Chen, Huan [3 ]
Zang, Hui [4 ]
Zhou, Hui [2 ]
Xiao, Ling [1 ]
机构
[1] Cent South Univ, Dept Histol & Embryol, Sch Basic Med Sci, Changsha, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Dept Lymphoma & Hematol, Changsha, Hunan, Peoples R China
[3] Hunan Univ Med, Sch Basic Med Sci, Dept Pathol & Pathophysiol, Huaihua 418000, Peoples R China
[4] Yiyang Med Coll, Dept Human Anat & Histoembryol, Sch Basic Med Sci, Yiyang, Peoples R China
来源
JOURNAL OF CANCER | 2022年 / 13卷 / 05期
基金
中国国家自然科学基金;
关键词
Key words; diffuse large B-cell Lymphoma (DLBCL); treatment; research progress; bibliometric analysis; Visualized; VOSviewer; PUBLIC-HEALTH RESEARCH; R-CHOP; PHASE-III; FRONTLINE RITUXIMAB; INFECTIOUS-DISEASES; SALVAGE REGIMENS; TRANSPLANTATION; LENALIDOMIDE; TRIAL; CYCLOPHOSPHAMIDE;
D O I
10.7150/jca.68453
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype. Treatment of DLBCL has improved greatly in recent decades, with thousands of papers published. We conducted a bibliometric analysis of the literature on DLBCL treatment, and discussed cooperation among authors, countries, and institutions, and identified research hotspots for DLBCL treatment. We searched the Web of Science Core Collection (WOSCC) using "Diffuse Large B Cell Lymphoma or DLBCL" and "Treatment or Therapy or Clinical Trial" as the subject terms, and analyzed the publication year, research direction, country/region, institution, author, source publication, distribution of funding institutions, and other conditions provided by the database. In addition, scientometrics software was used to analyze literature citations and cooperative publications. Bibliometric analyses were performed using https://bibliometric.com/app and VOSviewer. Network maps were generated to evaluate collaborations between different authors, countries, institutions, and keywords. A total of 7,255 studies on treatment of DLBCL were retrieved from the WOSCC on February 19, 2021. We found that the number of publications increased gradually from 1999 to 2021, and this trend was relatively stable in the past 3 years. The countries that produced the most publications were the United States, China, and Japan. Among institutions, University of Texas MD Anderson Cancer Center published the most manuscripts. Furthermore, the United States also had the most annual publications, citations, distribution of journal sources, and funding. Cooperative research between countries is also relatively important to treatment of DLBCL. Therapeutic regimens such as CHOP and R-CHOP, and immunotherapy (CAR-T, PD1/PDL1, and CAR-NK, etc.), have received increased attention. Bibliometric analysis of studies related to DLBCL treatment can help researchers and clinical workers quickly understand the hotspots and development trends in this field, and provide reference for the formulation of public health policies.
引用
收藏
页码:1785 / 1795
页数:11
相关论文
共 50 条
  • [21] Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma
    Roschewski, Mark
    Phelan, James D.
    Wilson, Wyndham H.
    CANCER JOURNAL, 2020, 26 (03) : 195 - 205
  • [22] Diffuse Large B-cell Lymphoma Diagnosis and Treatment in Kosovo
    Rrusta, Shpat
    Sadiku, Shemsedin
    Ukimeraj, Aferdita
    Berisha, Adriatik
    Gashi, Edlira
    Dakaj, Arbereshe
    Rrusta, Dile
    Berisha, Adriana
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S270 - S270
  • [23] Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma
    Pirosa, Maria Cristina
    Stathis, Anastasios
    Zucca, Emanuele
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [24] Treatment strategies for patients with diffuse large B-cell lymphoma
    Poletto, Stefano
    Novo, Mattia
    Paruzzo, Luca
    Frascione, Pio Manlio Mirko
    Vitolo, Umberto
    CANCER TREATMENT REVIEWS, 2022, 110
  • [25] Current treatment approaches for diffuse large B-cell lymphoma
    Illidge, Tim
    Tolan, Shaun
    LEUKEMIA & LYMPHOMA, 2008, 49 (04) : 663 - 676
  • [26] Current Frontline Treatment of Diffuse Large B-Cell Lymphoma
    Spinner, Michael A.
    Advani, Ranjana H.
    ONCOLOGY-NEW YORK, 2022, 36 (01): : 51 - 58
  • [27] CNS prophylaxis for diffuse large B-cell lymphoma
    Eyre, Toby A.
    Savage, Kerry J.
    Cheah, Chan Y.
    El-Galaly, Tarec C.
    Lewis, Katharine L.
    McKay, Pamela
    Wilson, Matthew R.
    Evens, Andrew M.
    Bobillo, Sabela
    Villa, Diego
    Maurer, Matthew J.
    Cwynarski, Kate
    Ferreri, Andres
    LANCET ONCOLOGY, 2022, 23 (09) : E416 - E426
  • [28] Biological heterogeneity in diffuse large B-cell lymphoma
    Hilton, Laura K.
    Scott, David W.
    Morin, Ryan D.
    SEMINARS IN HEMATOLOGY, 2023, 60 (05) : 267 - 276
  • [29] Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment
    Danilov, Alexey, V
    Magagnoli, Massimo
    Matasar, Matthew J.
    ONCOLOGIST, 2022, 27 (01) : 57 - 66
  • [30] Treatment Modalities and Survival Outcomes for Sinonasal Diffuse Large B-Cell Lymphoma
    Lehrich, Brandon M.
    Abiri, Arash
    Goshtasbi, Khodayar
    Birkenbeuel, Jack
    Yasaka, Tyler M.
    Papagiannopoulos, Peter
    Tajudeen, Bobby A.
    Brem, Elizabeth A.
    Kuan, Edward C.
    LARYNGOSCOPE, 2021, 131 (11) : E2727 - E2735